PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33249031-0	2021	Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia.	Levodopa	96-102	dopamine receptor D3	Rattus norvegicus	27-47	
33119328-1	2021	Dopamine D2/3 receptor agonists are less likely to trigger dyskinesias than L-dopa while still offering relief from the motor symptoms of Parkinson"s disease (PD).	Levodopa	76-82	dopamine receptor D3	Rattus norvegicus	0-22	
29936243-1	2018	Individually, D1 and D3 dopamine receptors (D1R and D3R, respectively) have been implicated in L-DOPA-induced dyskinesia (LID).	Levodopa	95-101	dopamine receptor D3	Rattus norvegicus	14-47	
20850462-0	2011	Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats.	Levodopa	84-90	dopamine receptor D3	Rattus norvegicus	18-38	
25914172-13	2015	These findings demonstrated that HSYA provided anti-dyskinetic relief against L-DOPA in a preclinical model of PD via regulating the expression of the dopamine D3 receptor.	Levodopa	78-84	dopamine receptor D3	Rattus norvegicus	151-171	
16814282-3	2006	Attenuation of levodopa-induced dyskinesia by normalizing dopamine D(3) receptor function.	Levodopa	15-23	dopamine receptor D3	Rattus norvegicus	58-80	
17241287-8	2007	After 3 days of washout, levodopa treatment maintained elevated striatal preproenkephalin mRNA expression, also inducing an increase in preprodynorphin (PDyn) and dopamine D-3 receptor mRNAs, but without any modification of the adenosine A(2A) mRNA expression induced by 6-OHDA.	Levodopa	25-33	dopamine receptor D3	Rattus norvegicus	163-184	
19118628-0	2009	Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson"s disease.	Levodopa	62-68	dopamine receptor D3	Rattus norvegicus	0-20	
19371585-0	2009	Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats.	Levodopa	71-77	dopamine receptor D3	Rattus norvegicus	18-38	
16814282-8	2006	Effect of the D(3) dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys.	Levodopa	122-150	dopamine receptor D3	Rattus norvegicus	14-36	
9096399-0	1997	Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa.	Levodopa	91-99	dopamine receptor D3	Rattus norvegicus	13-33	
14697317-10	2004	These data and previous studies suggest the involvement of enhanced opioid transmission in L-DOPA-induced dyskinesia and that part of the reason why D2/D3 dopamine receptor agonists have a reduced propensity to elicit dyskinesia may reside in their reduced ability to elevate opioid transmission.	Levodopa	91-97	dopamine receptor D3	Rattus norvegicus	152-172	
14623353-6	2003	Administration of a dopamine D3 receptor-selective partial agonist strongly attenuated levodopa-induced dyskinesia, while leaving unaffected the therapeutic effect of levodopa.	Levodopa	87-95	dopamine receptor D3	Rattus norvegicus	20-40	
14623353-7	2003	These results suggest that the dopamine D3 receptor participates in both dyskinesia and the therapeutic action of levodopa and that partial agonists may normalize dopamine D3 receptor function and correct side-effects of levodopa therapy in PD patients.	Levodopa	114-122	dopamine receptor D3	Rattus norvegicus	31-51	
14623353-7	2003	These results suggest that the dopamine D3 receptor participates in both dyskinesia and the therapeutic action of levodopa and that partial agonists may normalize dopamine D3 receptor function and correct side-effects of levodopa therapy in PD patients.	Levodopa	221-229	dopamine receptor D3	Rattus norvegicus	31-51	
12535962-0	2003	Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa.	Levodopa	116-124	dopamine receptor D3	Rattus norvegicus	40-60	
12535962-3	2003	Elevations in dopamine D(3) receptor mRNA and binding are seen in the denervated striatum of hemiparkinsonian rats treated chronically with levodopa, and these changes correlate well with behavioural sensitization in this model.	Levodopa	140-148	dopamine receptor D3	Rattus norvegicus	14-36	
12535962-4	2003	Further investigation of dopamine D(3) receptor involvement in levodopa-induced dyskinesias is hampered by the lack of appropriately selective ligands for this receptor.	Levodopa	63-71	dopamine receptor D3	Rattus norvegicus	25-47	
10886351-1	2000	Induction of dopamine D3 receptor gene expression in 6-hydroxydopamine-lesioned rats by repeated administration of levodopa had been suggested to be responsible for behavioural sensitization developing in these animals.	Levodopa	115-123	dopamine receptor D3	Rattus norvegicus	13-33